Early life treatment with vancomycin reduces diabetes incidence in NOD mice

Research output: Contribution to conferencePosterResearch

Type 1 diabetes (T1D) results from an uncontrolled T cell mediated destruction of the insulin-producing beta-cells in the pancreas. Causal factors include a combination of genetics, early life incidents and the food we eat. The involved adaptive immune response can be down regulated by a regulatory immune response and a fine-tuned balance between these immunological components is crucial for characteristics of the disease, such as severity, onset time and recovery.
The balance between the regulatory and the adaptive immune response is heavily influenced by early life bacterial stimulation. An interplay that is likely to represent a critical environmental component to diabetes induction. In a period after birth alterations of the early microbial colonization of the gut therefore can be expected to have an immense impact on diabetes progression later in life.
In this study neonate NOD mice were treated with the antibiotic vancomycin in four weeks from birth. Diabetes incidence and onset time were compared with a control group and we found that neonate vancomycin treatment attenuates T1D. By changing the gut flora composition in the beginning of life we also demonstrated a disruption of the mechanisms regulating intestinal immune homeostasis toward a proinflammatory mucosal environment.
Original languageEnglish
Publication dateApr 2011
Publication statusPublished - Apr 2011
EventMucosal Immunology and Health and Disease - San Fransisco, United States
Duration: 14 Apr 201116 Apr 2011


ConferenceMucosal Immunology and Health and Disease
CountryUnited States
CitySan Fransisco

ID: 37812499